Clinical Trial Update: Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA). [Phase 2]

View source ↗

Summary

Phase 2 trial update for prolonged-release pirfenidone in advanced residual liver fibrosis due to liver cirrhosis and chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Liver Cirrhosis

Drugs mentioned

• pirfenidone (prolonged-release) (pirfenidone)

Snippet

Sponsor: University of Guadalajara | Conditions: Liver Cirrhosis, Hepatitis C, Chronic | Phase 2 | Status: UNKNOWN